4:07 PM ET
8-K
Business Update
Bluejay Diagnostics Business Update
Bluejay Diagnostics provided a corporate update for Q3 2026, highlighting the completion of enrollment for its SYMON-II clinical study and the establishment of an alternative manufacturing site ahead of schedule. The company reported a cash balance of $7.38 million and targets an FDA 510(k) submission for its Symphony IL-6 platform in the first half of 2027.